Premenstrual dysphoric disorder and severe premenstrual syndrome in adolescents (Q38093136)

28 August 2017

Premenstrual dysphoric disorder and severe premenstrual syndrome in adolescents (English)

1 reference

28 August 2017

1 reference

premenstrual syndrome

1 reference

Andrea J Rapkin

1

1 reference

PubMed ID

23529867

28 August 2017

Judith A Mikacich

series ordinal

2

1 reference

28 August 2017

1 June 2013

1 reference

28 August 2017

1 reference

28 August 2017

15

1 reference

28 August 2017

3

1 reference

28 August 2017

191-202

1 reference

https://scigraph.springernature.com/pub.10.1007/s40272-013-0018-4

28 August 2017

0 references

cites work

Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Core symptoms that discriminate premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Characteristics of menstrual cycles in Moroccan girls: prevalence of dysfunctions and associated behaviours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Prevalence and correlates of perimenstrual symptoms: a study of Israeli teenage girls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Premenstrual disorders in Polish adolescent girls: prevalence and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

A comparison of the prevalence of premenstrual dysphoric disorder and comorbidities among adolescents in the United States of America and Nigeria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

The Premenstrual Symptoms Screening Tool revised for adolescents (PSST-A): prevalence of severe PMS and premenstrual dysphoric disorder in adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese high school students.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Prevalence, incidence and stability of premenstrual dysphoric disorder in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Menstrual disorders in adolescent school girls in Enugu, Nigeria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

The premenstrual symptoms screening tool (PSST) for clinicians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Premenstrual syndrome and associated symptoms in adolescent girls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Premenstrual symptoms. Prevalence and severity in an adolescent sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Premenstrual dysphoric disorder among medical students of a Nigerian university

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Continuous oral contraception: changing times

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Knowledge, attitudes, and consequences of menstrual health in urban adolescent females

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

The association between seasonal and premenstrual symptoms is continuous and is not fully accounted for by depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Firstborn adolescent daughters and mothers with and without premenstrual syndrome: a comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Relationship of adolescent physical and sexual abuse to perimenstrual symptoms (PMS) in adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Obesity as a risk factor for premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Premenstrual syndrome and dysmenorrhea: urban-rural and multiethnic differences in perception, impacts, and treatment seeking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Premenstrual syndrome: the experience from a sample of Sri Lankan adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Effects of calcium supplement therapy in women with premenstrual syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Diagnosis and management of premenstrual disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Update on research and treatment of premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Premenstrual dysphoric disorder in adolescents: case reports of treatment with fluoxetine and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Venlafaxine in the treatment of premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Clinical subtypes of premenstrual syndrome and responses to sertraline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Antidepressant use during pregnancy: the benefit-risk ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Premenstrual dysphoric disorder in an adolescent female

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Adolescent depression: challenges and opportunities: a review and current recommendations for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

The use of selective serotonin reuptake inhibitors in children and adolescents with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

An integrative medicine approach to premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

The pharmacologic management of premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

The Relationship Between Antidepressant Prescription Rates and Rate of Early Adolescent Suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0018-4

The association between premenstrual dysphoric disorder and other mood disorders

21 January 2018

1 reference

12 December 2020

Premenstrual dysphoric disorder--a neglected diagnosis? Preliminary study on a sample of Croatian students

1 reference

12 December 2020

The premenstrual syndrome: a twin study

1 reference

12 December 2020

Premenstrual syndrome (PMS) in adolescents: severity and impairment.

1 reference

12 December 2020

Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone

1 reference

12 December 2020

The relationship between antidepressant prescription rates and rate of early adolescent suicide

1 reference

12 December 2020

Menstruation among adolescent girls in Malaysia: a cross-sectional school survey.

1 reference

12 December 2020

Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome

1 reference

12 December 2020

A controlled study of light therapy in women with late luteal phase dysphoric disorder

1 reference

12 December 2020

Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.

1 reference

12 December 2020

The significance of "nonsignificance" in randomized controlled studies: a discussion inspired by a double-blinded study on St. John's wort (Hypericum perforatum L.) for premenstrual symptoms.

1 reference

12 December 2020

Genetic and environmental influences on premenstrual symptoms in an Australian twin sample

1 reference

12 December 2020

Premenstrual symptomatology and alcohol consumption in college women.

1 reference

12 December 2020

Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study

1 reference

12 December 2020

Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder.

1 reference

12 December 2020

The relationship between suicidal attempts and menstrual cycle in women.

1 reference

12 December 2020

Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies

1 reference

12 December 2020

Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant

1 reference

12 December 2020

Oral contraceptives containing drospirenone for premenstrual syndrome

1 reference

12 December 2020

Premenstrual exacerbation of depression: one process or two?

1 reference

12 December 2020

Premenstrual syndrome in adolescents: diagnosis and treatment.

1 reference

12 December 2020

Daily Record of Severity of Problems (DRSP): reliability and validity

1 reference

12 December 2020

Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder

1 reference

12 December 2020

The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study

1 reference

12 December 2020

Premenstrual syndrome

1 reference

12 December 2020

Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity

1 reference

12 December 2020

Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives

1 reference

12 December 2020

Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series

1 reference

12 December 2020

Calcium and vitamin D intake and risk of incident premenstrual syndrome

1 reference

12 December 2020

Effects of an educational programme on adolescents with premenstrual syndrome

1 reference

12 December 2020

When should GPs prescribe SSRIs for adolescent depression?

1 reference

12 December 2020

Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents

1 reference

12 December 2020

Personality factors in women with premenstrual syndrome

1 reference

12 December 2020

Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome.

1 reference

12 December 2020

Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder

1 reference

12 December 2020

Female reproductive cycle and obsessive-compulsive disorder

1 reference

12 December 2020

Hormone withdrawal symptoms in oral contraceptive users

1 reference

12 December 2020

10.1007/S40272-013-0018-4

Identifiers

DOI

1 reference

PubMed ID

23529867

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23529867